Adenoviral targeting of malignant melanoma for fluorescence-guided surgery prevents recurrence in orthotopic nude-mouse models
Metrics: PDF 633 views | HTML 996 views | ?
Shuya Yano1,2,3, Kiyoto Takehara1,2,3, Hiroyuki Kishimoto3, Yasuo Urata4, Shunsuke Kagawa3, Michael Bouvet2, Toshiyoshi Fujiwara3, Robert M. Hoffman1,2
1AntiCancer, Inc., San Diego, CA, USA
2Department of Surgery, University of California San Diego, La Jolla, CA, USA
3Department of Gastroenterological Surgery, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
4Oncolys BioPharm Inc., Tokyo, Japan
Robert M. Hoffman, e-mail: email@example.com
Toshiyoshi Fujiwara, e-mail: firstname.lastname@example.org
Keywords: melanoma, nude mice, fluorescence-guided surgery (FGS), adenovirus, OBP-401
Abbreviations: GFP, green fluorescent protein; RFP, red fluorescent protein; FGS, fluorescence-guided surgery; BLS, bright-light surgery
Received: September 17, 2015 Accepted: November 27, 2015 Published: December 18, 2015
Malignant melanoma requires precise resection in order to avoid metastatic recurrence. We report here that the telomerase-dependent, green fluorescent protein (GFP)-containing adenovirus OBP-401 could label malignant melanoma with GFP in situ in orthotopic mouse models. OBP-401-based fluorescence-guided surgery (FGS) resulted in the complete resection of malignant melanoma in the orthotopic models, where conventional bright-light surgery (BLS) could not. High-dose administration of OBP-401 enabled FGS without residual cancer cells or recurrence, due to its dual effect of cancer-cell labeling with GFP and killing.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.